Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:46 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,904 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: AstraZeneca Clear all
Recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
27
States / cities
Birmingham, Alabama • Daphne, Alabama • Lomita, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)

NCT00915538
View directory record Official record
Conditions
Asthma
Interventions
pMDI budesonide/formotrol 160/4.5 is in group 1, Symbicort 160/4.5 plus Aerochamber Plus included in group 2
Drug · Device
Lead sponsor
Western Sky Medical Research
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 3 Interventional

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

NCT01876849
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Nov 2, 2026, 10:46 PM EST
Completed No phase listed Observational Results available

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

NCT00229658
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
107
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

NCT01974349
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib (oral)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Nov 2, 2026, 10:46 PM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

NCT03263091
View directory record Official record
Conditions
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
30
States / cities
Bakersfield, California • Beverly Hills, California • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 2 Interventional Results available

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

NCT03688074
View directory record Official record
Conditions
Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Nov 2, 2026, 10:46 PM EST
Not listed No phase listed Observational

A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers

NCT01936376
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Nov 2, 2026, 10:46 PM EST
Completed No phase listed Observational

Prospective Tissue Collection Research Protocol

NCT03517917
View directory record Official record
Conditions
Solid Tumor
Interventions
Tumour tissue collection
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Georgetown, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Nov 2, 2026, 10:46 PM EST
Completed No phase listed Observational

Longitudinal Study of Patients With Opioid-Induced Constipation

NCT01928953
View directory record Official record
Conditions
Patients With Opioid Induced Constipation
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 3 Interventional Results available

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

NCT00880919
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
quetiapine extended-release, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Iowa City, Iowa • Belmont, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

NCT00163514
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
58
States / cities
Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Nov 2, 2026, 10:46 PM EST
Active, not recruiting Phase 3 Interventional

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 2 Interventional Results available

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

NCT03990363
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Verinurad, Allopurinol, Placebo for Verinurad, Placebo for Allopurinol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Bakersfield, California • Canyon Country, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Nov 2, 2026, 10:46 PM EST
Active, not recruiting Phase 3 Interventional Results available

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

NCT03875235
View directory record Official record
Conditions
Biliary Tract Neoplasms
Interventions
Durvalumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fostamatinib in Subjects With Impaired Kidney Function

NCT01245790
View directory record Official record
Conditions
Rheumatoid Arthritis, Renal Impairment
Interventions
fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

NCT01031680
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
60
States / cities
Gulf Shores, Alabama • Phoenix, Arizona • Burbank, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 3 Interventional Results available

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

NCT01434186
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo matching with Saxagliptin, Metformin IR, Metformin XR, Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Tallahassee, Florida • Dearborn, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 1 Interventional

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

NCT01176097
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD5658, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 3 Interventional Results available

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Nov 2, 2026, 10:46 PM EST
Completed Phase 2 Interventional

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

NCT03263650
View directory record Official record
Conditions
Prostate Cancer Aggressiveness, Prostate Carcinoma
Interventions
Cabazitaxel, Carboplatin, Prednisone 5Mg, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 2, 2026, 10:46 PM EST
Recruiting No phase listed Observational

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810
View directory record Official record
Conditions
Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
Interventions
Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
33
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 2, 2026, 10:46 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

NCT07717840
View directory record Official record
Conditions
RSV Respiratory Syncytial Virus
Interventions
AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 2, 2026, 10:46 PM EST
Active, not recruiting Phase 3 Interventional

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 18 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Torrance, California • Ocala, Florida • Owensboro, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 2, 2026, 10:46 PM EST